U.S. markets closed
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • Dow 30

    34,584.88
    -166.44 (-0.48%)
     
  • Nasdaq

    15,043.97
    -137.96 (-0.91%)
     
  • Russell 2000

    2,236.87
    +3.96 (+0.18%)
     
  • Crude Oil

    71.96
    -0.65 (-0.90%)
     
  • Gold

    1,753.90
    -2.80 (-0.16%)
     
  • Silver

    22.36
    -0.43 (-1.90%)
     
  • EUR/USD

    1.1732
    -0.0040 (-0.34%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • GBP/USD

    1.3737
    -0.0059 (-0.43%)
     
  • USD/JPY

    109.8950
    +0.1770 (+0.16%)
     
  • BTC-USD

    47,646.38
    -801.82 (-1.65%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.62%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

New Strong Sell Stocks for May 28th

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Here are five stocks added to the Zacks Rank #5 (Strong Sell) List today:

Adicet Bio, Inc. ACET is a biopharmaceutical company that discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The Zacks Consensus Estimate for its current year earnings has been revised 10% downward over the last 30 days.

Fury Gold Mines Limited FURY operates as an exploration and development company. The Zacks Consensus Estimate for its current year earnings has been revised 44.4% downward over the last 30 days.

Krystal Biotech, Inc. KRYS is a clinical stage biotechnology company that engages in the field of redosable gene therapy to treat serious rare diseases. The Zacks Consensus Estimate for its current year earnings has been revised 22.5% downward over the last 30 days.

Mersana Therapeutics, Inc. MRSN is a clinical stage biopharmaceutical company that focuses on the development of antibody drug conjugates. The Zacks Consensus Estimate for its current year earnings has been revised 16.4% downward over the last 30 days.

NewAge, Inc. NBEV develops, markets, sells, and distributes healthy products. The Zacks Consensus Estimate for its current year earnings has been revised more than 100% downward over the last 30 days.

View the entire Zacks Rank #5 List.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Adicet Bio, Inc. (ACET) : Free Stock Analysis Report
 
NewAge, Inc. (NBEV) : Free Stock Analysis Report
 
Krystal Biotech, Inc. (KRYS) : Free Stock Analysis Report
 
Mersana Therapeutics, Inc. (MRSN) : Free Stock Analysis Report
 
Fury Gold Mines Limited (FURY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research